Compare SOLAI Limited (SLAI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SOLAI Limited vs State Street SPDR S&P Biotech ETF — how do they compare? SOLAI Limited trades at $3.72 (market cap $880.09M), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 11.5× SOLAI Limited's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, SOLAI Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold SOLAI Limited for 40 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| SLAI | XBI | |
|---|---|---|
Market Cap | $880.09M | $10.11B |
Volume | 122,720 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $21.63 | $169.55 |
52-Week Low | $2.74 | $104.99 |
Typical Hold Time | 40 Days | 38 Days |
Enterprise Value | $879.73M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLAI trades at $3.72 with no recent price movement. The stock shows a bullish technical signal despite concerning fundamentals, including negative profit margins (-134.76% net income margin) and declining revenue from $57M in 2022 to $23M in 2025. The company received a delisting notice from NYSE in July 2026, creating significant uncertainty. Cash flow remains negative at -$1.47M, though the P/B ratio of 0.35 suggests potential undervaluation based on book value.
Outlook remains highly speculative given delisting proceedings and persistent losses. The single analyst covering the stock maintains a Hold rating, reflecting cautious sentiment. Investment opportunity exists only for risk-tolerant investors betting on turnaround potential, while major risks include delisting execution, continued cash burn, and competitive pressures in the AI infrastructure space.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
